EAGLE PHARMACEUTICALS INC (EGRX)
US2697961082 - Common Stock
Taking everything into account, EGRX scores 4 out of 10 in our fundamental rating. EGRX was compared to 568 industry peers in the Biotechnology industry. EGRX scores excellent on profitability, but there are concerns on its financial health. EGRX has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year EGRX was profitable.
In the past year EGRX has reported a negative cash flow from operations.
Of the past 5 years EGRX 4 years were profitable.
In the past 5 years EGRX always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 2.99%, EGRX belongs to the best of the industry, outperforming 94.01% of the companies in the same industry.
Looking at the Return On Equity, with a value of 4.80%, EGRX belongs to the top of the industry, outperforming 94.54% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 10.53%, EGRX belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for EGRX is in line with the industry average of 13.59%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| ROIC | 10.53% |
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
1.3 Margins
With an excellent Profit Margin value of 4.70%, EGRX belongs to the best of the industry, outperforming 94.19% of the companies in the same industry.
EGRX's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 16.47%, EGRX belongs to the top of the industry, outperforming 95.77% of the companies in the same industry.
EGRX's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 69.86%, EGRX belongs to the best of the industry, outperforming 84.33% of the companies in the same industry.
In the last couple of years the Gross Margin of EGRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.47% | ||
| PM (TTM) | 4.7% | ||
| GM | 69.86% |
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), EGRX is creating some value.
EGRX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, EGRX has less shares outstanding
Compared to 1 year ago, EGRX has a worse debt to assets ratio.
2.2 Solvency
EGRX has an Altman-Z score of 1.81. This is not the best score and indicates that EGRX is in the grey zone with still only limited risk for bankruptcy at the moment.
EGRX has a better Altman-Z score (1.81) than 70.07% of its industry peers.
EGRX has a Debt/Equity ratio of 0.25. This is a healthy value indicating a solid balance between debt and equity.
EGRX's Debt to Equity ratio of 0.25 is on the low side compared to the rest of the industry. EGRX is outperformed by 68.84% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.81 |
ROIC/WACC1.32
WACC7.97%
2.3 Liquidity
A Current Ratio of 2.16 indicates that EGRX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.16, EGRX is doing worse than 75.35% of the companies in the same industry.
EGRX has a Quick Ratio of 1.67. This is a normal value and indicates that EGRX is financially healthy and should not expect problems in meeting its short term obligations.
EGRX's Quick ratio of 1.67 is on the low side compared to the rest of the industry. EGRX is outperformed by 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.16 | ||
| Quick Ratio | 1.67 |
3. Growth
3.1 Past
The earnings per share for EGRX have decreased strongly by -33.52% in the last year.
EGRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.81% yearly.
The Revenue has decreased by -5.40% in the past year.
EGRX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.99% yearly.
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
3.2 Future
EGRX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -11.47% yearly.
EGRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.24% yearly.
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 0.46, the valuation of EGRX can be described as very cheap.
99.82% of the companies in the same industry are more expensive than EGRX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.73, EGRX is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 0.64, the valuation of EGRX can be described as very cheap.
Based on the Price/Forward Earnings ratio, EGRX is valued cheaply inside the industry as 99.65% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.83. EGRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.46 | ||
| Fwd PE | 0.64 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, EGRX is valued cheaply inside the industry as 99.12% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.31 |
4.3 Compensation for Growth
EGRX has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as EGRX's earnings are expected to decrease with -26.94% in the coming years.
PEG (NY)N/A
PEG (5Y)0.03
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
5. Dividend
5.1 Amount
No dividends for EGRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EAGLE PHARMACEUTICALS INC
NASDAQ:EGRX (10/2/2024, 8:06:00 PM)
After market: 2.28 +0.14 (+6.54%)2.14
-1.42 (-39.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners66.05%
Inst Owner Change-13.27%
Ins Owners5.97%
Ins Owner Change0%
Market Cap27.80M
Analysts85.71
Price Target17.34 (710.28%)
Short Float %3.08%
Short Ratio1.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.91%
Min EPS beat(2)10.18%
Max EPS beat(2)17.65%
EPS beat(4)4
Avg EPS beat(4)19.72%
Min EPS beat(4)10.18%
Max EPS beat(4)29.93%
EPS beat(8)5
Avg EPS beat(8)-2.39%
EPS beat(12)8
Avg EPS beat(12)72.12%
EPS beat(16)11
Avg EPS beat(16)63.08%
Revenue beat(2)2
Avg Revenue beat(2)4.74%
Min Revenue beat(2)2.71%
Max Revenue beat(2)6.76%
Revenue beat(4)3
Avg Revenue beat(4)1.54%
Min Revenue beat(4)-7.39%
Max Revenue beat(4)6.76%
Revenue beat(8)3
Avg Revenue beat(8)-9.26%
Revenue beat(12)5
Avg Revenue beat(12)-7.18%
Revenue beat(16)5
Avg Revenue beat(16)-7.22%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.46 | ||
| Fwd PE | 0.64 | ||
| P/S | 0.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.11 | ||
| P/tB | 0.28 | ||
| EV/EBITDA | 1.31 |
EPS(TTM)4.66
EY217.76%
EPS(NY)3.34
Fwd EY155.86%
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS19.82
BVpS19.4
TBVpS7.67
PEG (NY)N/A
PEG (5Y)0.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.99% | ||
| ROE | 4.8% | ||
| ROCE | 13.33% | ||
| ROIC | 10.53% | ||
| ROICexc | 11.06% | ||
| ROICexgc | 22.27% | ||
| OM | 16.47% | ||
| PM (TTM) | 4.7% | ||
| GM | 69.86% | ||
| FCFM | N/A |
ROA(3y)3.37%
ROA(5y)5.82%
ROE(3y)5.61%
ROE(5y)8.93%
ROIC(3y)13.59%
ROIC(5y)13.5%
ROICexc(3y)19.91%
ROICexc(5y)21.41%
ROICexgc(3y)52.27%
ROICexgc(5y)50.12%
ROCE(3y)17.2%
ROCE(5y)17.09%
ROICexcg growth 3Y46.01%
ROICexcg growth 5Y-6.15%
ROICexc growth 3Y27.58%
ROICexc growth 5Y-11.05%
OM growth 3Y42.71%
OM growth 5Y-1.58%
PM growth 3Y15.49%
PM growth 5Y-12.5%
GM growth 3Y0.54%
GM growth 5Y-1.58%
F-Score3
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.25 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 0.34% | ||
| Cap/Sales | 0.03% | ||
| Interest Coverage | 10.44 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.16 | ||
| Quick Ratio | 1.67 | ||
| Altman-Z | 1.81 |
F-Score3
WACC7.97%
ROIC/WACC1.32
Cap/Depr(3y)10.4%
Cap/Depr(5y)10.3%
Cap/Sales(3y)0.21%
Cap/Sales(5y)0.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.52%
EPS 3Y44.53%
EPS 5Y14.81%
EPS Q2Q%-24.36%
EPS Next Y-40.26%
EPS Next 2Y-34.69%
EPS Next 3Y-26.94%
EPS Next 5Y-11.47%
Revenue 1Y (TTM)-5.4%
Revenue growth 3Y17.35%
Revenue growth 5Y5.99%
Sales Q2Q%-12.76%
Revenue Next Year-19.31%
Revenue Next 2Y-18.72%
Revenue Next 3Y-11.22%
Revenue Next 5Y0.24%
EBIT growth 1Y-45.5%
EBIT growth 3Y67.47%
EBIT growth 5Y4.32%
EBIT Next Year-37.58%
EBIT Next 3Y-26.19%
EBIT Next 5YN/A
FCF growth 1Y-121.43%
FCF growth 3Y-2.92%
FCF growth 5Y-1.22%
OCF growth 1Y-120.96%
OCF growth 3Y-3.25%
OCF growth 5Y-2.96%